- Home
- BRNS vs JSPR Comparison
BRNS vs JSPR Comparison
Compare BRNS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 48.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRNS | JSPR |
|---|---|---|
| Price | $0.71 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $4.00 | ★ $21.44 |
| AVG Volume (30 Days) | 75.2K | ★ 4.0M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1766.46 | N/A |
| 52 Week Low | $0.64 | $1.39 |
| 52 Week High | $2.92 | $22.99 |
Technical Indicators
Market Signals| Indicator | BRNS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 47.03 |
| Support Level | $0.68 | $1.61 |
| Resistance Level | $0.74 | $1.96 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 48.02 | 46.25 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.